Stock Events

Stock Events

Minerva Neurosciences 

$4.47
65
+$0.28+6.68% Thursday 20:00

Statistics

Day High
4.65
Day Low
4.06
52W High
8.07
52W Low
1.63
Volume
574,948
Avg. Volume
-
Mkt Cap
31.26M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-2.86
-0.92
1.03
2.97
Expected EPS
-0.193333
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
0Revenue
2.88MNet Income

Analyst Ratings

10.50Average Price Target
The highest estimate is 14.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NERV. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.61B
Acadia Pharmaceuticals specializes in neurology, competing with Minerva in developing treatments for central nervous system disorders.
Alkermes
ALKS
Mkt Cap7.39B
Alkermes works on central nervous system (CNS) diseases, including schizophrenia and depression, areas Minerva is also targeting.
BridgeBio Pharma
BBIO
Mkt Cap13.08B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could overlap with Minerva's focus on neurological conditions.
Biogen
BIIB
Mkt Cap29.53B
Biogen is a major player in neurology, directly competing with Minerva in the broader market for neurological disease treatments.
AMGEN
AMGN
Mkt Cap191.7B
Amgen, with its broad focus on biopharmaceuticals, has ventures into neuroscience, making it a competitor in the neurology space.
Insmed
INSM
Mkt Cap21.21B
Insmed incorporates a wide range of therapeutic areas, including neurological diseases, indirectly competing with Minerva.
Ionis Pharmaceuticals
IONS
Mkt Cap12.11B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, which includes treatments for neurological disorders, competing with Minerva's focus.
Palatin Technologies
PTN
Mkt Cap24.21M
Palatin Technologies, though focused on different areas, has shown interest in expanding into central nervous system disorders, potentially competing with Minerva.

About

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Show more...
CEO
Dr. Remy Luthringer Ph.D.
Employees
8
Country
United States
ISIN
US6033802058

Listings

STU
DE
4MNA.STU
MU
DE
4MNA.MU
F
DE
4MNA.F
XNAS
US
NERV

0 Comments

Share your thoughts

FAQ

What is Minerva Neurosciences stock price today?▼
The current price of NERV is $4.47 USD — it has increased by +6.68% in the past 24 hours. Watch Minerva Neurosciences stock price performance more closely on the chart.
What is Minerva Neurosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Minerva Neurosciences stocks are traded under the ticker NERV.
Is Minerva Neurosciences stock price growing?▼
NERV stock has fallen by -0.89% compared to the previous week, the month change is a -11.13% fall, over the last year Minerva Neurosciences has showed a +152.54% increase.
What is Minerva Neurosciences market cap?▼
Today Minerva Neurosciences has the market capitalization of 31.26M
When is the next Minerva Neurosciences earnings date?▼
Minerva Neurosciences is going to release the next earnings report on August 04, 2026.
What were Minerva Neurosciences earnings last quarter?▼
NERV earnings for the last quarter are -2.86 USD per share, whereas the estimation was -0.13 USD resulting in a -2,157.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Minerva Neurosciences revenue for the last year?▼
Minerva Neurosciences revenue for the last year amounts to 0 USD.
What is Minerva Neurosciences net income for the last year?▼
NERV net income for the last year is 2.88M USD.
How many employees does Minerva Neurosciences have?▼
As of June 20, 2026, the company has 8 employees.
In which sector is Minerva Neurosciences located?▼
Minerva Neurosciences operates in the Health & Wellness sector.
When did Minerva Neurosciences complete a stock split?▼
The last stock split for Minerva Neurosciences was on June 21, 2022 with a ratio of 1:8.
Where is Minerva Neurosciences headquartered?▼
Minerva Neurosciences is headquartered in Burlington, United States.